The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine.
The researchers, led by Jeanne Sibiude from the INSERM, Centre for Research in Epidemiology and Population Health, used a large national health database, the French Perinatal Cohort, (ANRS CO1/CO11) which contains information on HIV-infected mothers who delivered infants in 90 centers throughout France. The researchers included 13,124 children who were born between 1994 and 2010 and had been exposed to antiretroviral therapy during pregnancy. Using two birth defect classification systems (EUROCAT and MACDP) the researchers investigated the link between birth defects and exposure to individual antiretroviral drugs.
Although limited by the absence of data on termination of pregnancy, stillbirths, tobacco and alcohol intake, and concomitant medication, the authors found a small increase in the risk for heart defects in children exposed to zidovudine using both classification systems (an absolute risk of +1.2%) and a possible association between efavirenz exposure and neurological defects, but only when using the MACDP classification system (an absolute risk of + 0.7%).
The authors found no association between several other antiretroviral drugs, including nevirapine (a drug in the NNRTI family, like efavirenz); tenofovir, stavudine, and abacavir (drugs in the NRTI family, like zidovudine); and lopinavir and ritonavir (drugs in the protease inhibitor family) and any type of birth defect.
The authors stress: "Whatever the impact that some [antiretroviral] drugs may have on birth defects, it is surpassed by the major role of [antiretroviral therapy] in the successful prevention of mother-to-child transmission of HIV."
In an accompanying Perspective, US experts Lynne Mofenson from the National Institutes of Health and Heather Watts from the Office of the Global AIDS Coordinator say: "While the Sibiude study raises some important questions, given the enormous benefits of maternal antiretroviral drugs, the unclear clinical significance of the heart defects and the lack of a specific pattern of CNS defects with efavirenz, no change in prescribing practices is indicated, but continued surveillance is critical."
Explore further: Malnutrition decreases effectiveness of HIV treatment in pregnant African women
More information: Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, et al. (2014) Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLoS Med 11(4): e1001635. DOI: 10.1371/journal.pmed.1001635
Medical Xpress on facebook
Related Stories
Malnutrition decreases effectiveness of HIV treatment in pregnant African women
Feb 18, 2014
In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge ...
Anti-HIV drug tenofovir is safe to take during pregnancy
May 15, 2012
Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, ...
Prevention of mother-child transmission programs work but infants need checking for drug resistance
Mar 29, 2011
Genetic mutations that lead to antiretroviral (the drugs used to treat HIV/AIDS) resistance in HIV-infected infants may develop as a result of exposure to low doses of maternal antiretroviral drugs via breastfeeding rather ...
Antiretroviral regimen associated with less virological failure among HIV-infected children
Apr 30, 2013
Elizabeth D. Lowenthal, M.D., M.S.C.E., of the University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, and colleagues conducted a study to determine whether there was a difference in ...
NIH studies influence revision of WHO guidelines for treating HIV-infected women, infants
Oct 13, 2010
Two studies appearing in the October 14, 2010 New England Journal of Medicine and funded by the National Institutes of Health helped influence the World Health Organization (WHO) to change its guidelines this year for th ...
Recommended for you
Coral reefs provide potent new anti-HIV proteins
7 hours ago
Researchers have discovered a new class of proteins capable of blocking the HIV virus from penetrating T-cells, raising hope that the proteins could be adapted for use in gels or sexual lubricants to provide a potent barrier ...
Low cholesterol in immune cells tied to slow progression of HIV
17 hours ago
People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public ...
Researchers trace HIV evolution in North America (Update)
Apr 24, 2014
A study tracing the evolution of HIV in North America involving researchers at Simon Fraser University has found evidence that the virus is slowly adapting over time to its human hosts. However, this change ...
Scientists discover how a killer fungus attacks HIV patients
Apr 23, 2014
Researchers have discovered that a type of white blood cell carries a deadly fungus into the brains of HIV positive patients, causing meningitis which kills more than 600,000 people a year.
Catching more than fish: Ugandan town crippled by AIDS
Apr 23, 2014
When you risk your life fishing on dangerous seas, a drink in the bars back on shore seem a welcome relief, but in Uganda, it has created a culture with staggering rates of HIV.
Harm-reduction program optimizes HIV/AIDS prevention
Apr 21, 2014
(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...
User comments
© Medical Xpress 2011-2014, Science X network
The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine.
The researchers, led by Jeanne Sibiude from the INSERM, Centre for Research in Epidemiology and Population Health, used a large national health database, the French Perinatal Cohort, (ANRS CO1/CO11) which contains information on HIV-infected mothers who delivered infants in 90 centers throughout France. The researchers included 13,124 children who were born between 1994 and 2010 and had been exposed to antiretroviral therapy during pregnancy. Using two birth defect classification systems (EUROCAT and MACDP) the researchers investigated the link between birth defects and exposure to individual antiretroviral drugs.
Although limited by the absence of data on termination of pregnancy, stillbirths, tobacco and alcohol intake, and concomitant medication, the authors found a small increase in the risk for heart defects in children exposed to zidovudine using both classification systems (an absolute risk of +1.2%) and a possible association between efavirenz exposure and neurological defects, but only when using the MACDP classification system (an absolute risk of + 0.7%).
The authors found no association between several other antiretroviral drugs, including nevirapine (a drug in the NNRTI family, like efavirenz); tenofovir, stavudine, and abacavir (drugs in the NRTI family, like zidovudine); and lopinavir and ritonavir (drugs in the protease inhibitor family) and any type of birth defect.
The authors stress: "Whatever the impact that some [antiretroviral] drugs may have on birth defects, it is surpassed by the major role of [antiretroviral therapy] in the successful prevention of mother-to-child transmission of HIV."
In an accompanying Perspective, US experts Lynne Mofenson from the National Institutes of Health and Heather Watts from the Office of the Global AIDS Coordinator say: "While the Sibiude study raises some important questions, given the enormous benefits of maternal antiretroviral drugs, the unclear clinical significance of the heart defects and the lack of a specific pattern of CNS defects with efavirenz, no change in prescribing practices is indicated, but continued surveillance is critical."
Explore further: Malnutrition decreases effectiveness of HIV treatment in pregnant African women
More information: Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, et al. (2014) Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLoS Med 11(4): e1001635. DOI: 10.1371/journal.pmed.1001635
Medical Xpress on facebook
Related Stories
Malnutrition decreases effectiveness of HIV treatment in pregnant African women
Feb 18, 2014
In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge ...
Anti-HIV drug tenofovir is safe to take during pregnancy
May 15, 2012
Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, ...
Prevention of mother-child transmission programs work but infants need checking for drug resistance
Mar 29, 2011
Genetic mutations that lead to antiretroviral (the drugs used to treat HIV/AIDS) resistance in HIV-infected infants may develop as a result of exposure to low doses of maternal antiretroviral drugs via breastfeeding rather ...
Antiretroviral regimen associated with less virological failure among HIV-infected children
Apr 30, 2013
Elizabeth D. Lowenthal, M.D., M.S.C.E., of the University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, and colleagues conducted a study to determine whether there was a difference in ...
NIH studies influence revision of WHO guidelines for treating HIV-infected women, infants
Oct 13, 2010
Two studies appearing in the October 14, 2010 New England Journal of Medicine and funded by the National Institutes of Health helped influence the World Health Organization (WHO) to change its guidelines this year for th ...
Recommended for you
Coral reefs provide potent new anti-HIV proteins
7 hours ago
Researchers have discovered a new class of proteins capable of blocking the HIV virus from penetrating T-cells, raising hope that the proteins could be adapted for use in gels or sexual lubricants to provide a potent barrier ...
Low cholesterol in immune cells tied to slow progression of HIV
17 hours ago
People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public ...
Researchers trace HIV evolution in North America (Update)
Apr 24, 2014
A study tracing the evolution of HIV in North America involving researchers at Simon Fraser University has found evidence that the virus is slowly adapting over time to its human hosts. However, this change ...
Scientists discover how a killer fungus attacks HIV patients
Apr 23, 2014
Researchers have discovered that a type of white blood cell carries a deadly fungus into the brains of HIV positive patients, causing meningitis which kills more than 600,000 people a year.
Catching more than fish: Ugandan town crippled by AIDS
Apr 23, 2014
When you risk your life fishing on dangerous seas, a drink in the bars back on shore seem a welcome relief, but in Uganda, it has created a culture with staggering rates of HIV.
Harm-reduction program optimizes HIV/AIDS prevention
Apr 21, 2014
(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment